A Modified Formulation of Zoono® Has Enhanced Efficacy against Bacterial Biofilms
Dr Sam Hale, ORL Registrar/PhD student, The University of Auckland, New Zealand
Authors List
Introduction
The presence of sinonasal bacterial biofilms in chronic rhinosinusitis (CRS), particularly those composed of Staphylococcus aureus, are associated with greater severity and recalcitrance. However, there are few effective topical products available to treat them. Zoono® is a widely available quaternary ammonium compound-based hand sanitiser that may have antibiofilm efficacy. Accordingly, this agent has promise as a therapeutic agent for the management of biofilm-associated CRS.
Aim
To determine the efficacy of Zoono® and Zoono® B22-1402A formulation against S. aureus and P. aeruginosa biofilms grown in vitro.
Methods
Biofilms were grown using the Centers for Disease Control (CDC) biofilm reactor and the Calgary Biofilm Device. Biofilms grown in each model were treated for 5 mins, 1 hour, 6 hours or overnight in Zoono®, Zoono® B22-1402A, or 0.9% saline (control). Viable bacteria remaining after treatment were cultured and enumerated by colony counting.
Results
In biofilms grown in the CDC biofilm reactor, Zoono® caused minimal reductions in viable S. aureus at all timepoints. A 4.1 log10 reduction at 6 hours and 5.8 log10 reduction overnight in viable P. aeruginosa was observed compared to control. Treatment with Zoono® B22-1402A resulted in a 6.2 log10 reduction in viable S. aureus at 1 hour and eradication at 6 hours. Zoono® B22-1402A caused a 4.2 log10 reduction in viable P. aeruginosa at 5 min and near eradication by 1 hour.
In biofilms grown in the Calgary Biofilm Device, both formulations eradicated S. aureus biofilm by 1 hour. Zoono® B22-1402A eradicated P. aeruginosa biofilm at 1 hour, and Zoono® achieved near eradication at 6 hours.
Conclusions
Both Zoono® formulations demonstrated antibiofilm activity, with Zoono® B22-1402A demonstrating greater potency. Biofilms grown in the Calgary Biofilm Device were more susceptible to the effects of antiseptics than those grown in the CDC biofilm reactor.
- Hale, S. J. M.
- Lux, C. A.
- Kim, R.
- Biswas, K.
- Wagner Mackenzie, B.
- Douglas, R. G.
Introduction
The presence of sinonasal bacterial biofilms in chronic rhinosinusitis (CRS), particularly those composed of Staphylococcus aureus, are associated with greater severity and recalcitrance. However, there are few effective topical products available to treat them. Zoono® is a widely available quaternary ammonium compound-based hand sanitiser that may have antibiofilm efficacy. Accordingly, this agent has promise as a therapeutic agent for the management of biofilm-associated CRS.
Aim
To determine the efficacy of Zoono® and Zoono® B22-1402A formulation against S. aureus and P. aeruginosa biofilms grown in vitro.
Methods
Biofilms were grown using the Centers for Disease Control (CDC) biofilm reactor and the Calgary Biofilm Device. Biofilms grown in each model were treated for 5 mins, 1 hour, 6 hours or overnight in Zoono®, Zoono® B22-1402A, or 0.9% saline (control). Viable bacteria remaining after treatment were cultured and enumerated by colony counting.
Results
In biofilms grown in the CDC biofilm reactor, Zoono® caused minimal reductions in viable S. aureus at all timepoints. A 4.1 log10 reduction at 6 hours and 5.8 log10 reduction overnight in viable P. aeruginosa was observed compared to control. Treatment with Zoono® B22-1402A resulted in a 6.2 log10 reduction in viable S. aureus at 1 hour and eradication at 6 hours. Zoono® B22-1402A caused a 4.2 log10 reduction in viable P. aeruginosa at 5 min and near eradication by 1 hour.
In biofilms grown in the Calgary Biofilm Device, both formulations eradicated S. aureus biofilm by 1 hour. Zoono® B22-1402A eradicated P. aeruginosa biofilm at 1 hour, and Zoono® achieved near eradication at 6 hours.
Conclusions
Both Zoono® formulations demonstrated antibiofilm activity, with Zoono® B22-1402A demonstrating greater potency. Biofilms grown in the Calgary Biofilm Device were more susceptible to the effects of antiseptics than those grown in the CDC biofilm reactor.
